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ABSTRACT
The receptor for the urokinase-type plasminogen activator (uPAR) accounts 
for many features of cancer progression, and is therefore considered a target for 
anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-
metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results into the loss 
of invasion properties and angiogenesis. MMP12 can be employed in the field of 
“targeted therapies” as a biological drug to be delivered directly in patient’s tumor 
mass. Endothelial Progenitor Cells (EPCs) are selectively recruited within the tumor 
and could be used as cellular vehicles for delivering anti-cancer molecules. The aim 
of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, 
with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. Ex vivo 
manipulated ECFCs lost the capacity to perform capillary morphogenesis and acquired 
the anti-tumor and anti-angiogenetic activity. In vivo MMP12-engineered ECFCs 
cleaved uPAR within the tumor mass and strongly inhibited tumor growth, tumor 
angiogenesis and development of lung metastasis.
The possibility to exploit tumor homing and activity of autologous MMP12-
engineered ECFCs represents a novel way to combat melanoma by a “personalized 
therapy”, without rejection risk.
The i.v. injection of radiolabelled MMP12-ECFCs can thus provide a new 
theranostic approach to control melanoma progression and metastasis.
INTRODUCTION
Many data of the last decades have demonstrated 
that the urokinase plasminogen activator system 
(urokinase-type plasminogen activator, uPA; uPA receptor, 
uPAR; uPA inhibitor type-1, PAI-1) plays a central role in 
the progression, metastasis, angiogenesis and stemness of 
numerous solid tumors [1-4]. Endogenous levels of uPA 
and uPAR increase with disease progression, correlate 
with poor prognosis and therefore can be considered a 
good target for anti-tumoral therapy [5]. This membrane-
associated system has reached the higher level-of-
evidence (level-1) ever for any biomarker in node-positive 
breast cancer and is actually considered the main system 
involved in tumor invasion and metastasis, as well as 
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in tumor angiogenesis [6]. uPAR is critical in invasive 
properties of malignant cells since it is involved both 
in extracellular matrix (ECM) degradation and in cell 
adhesion through a “grip-and-go” mechanism [7]. uPAR 
consists of 3 globular domains (D1, D2, D3) and is present 
on the cell membrane both as a full-length and a truncated 
molecule (D2+D3) which lacks the external uPA-binding 
D1 domain. However, only full length uPAR is able to 
mediate uPAR-dependent angiogenesis and invasion of 
cancer cells. In fact, MMP12-dependent uPAR cleavage 
impairs cell invasivity and angiogenesis [8-9] and uPAR 
truncation by transient transfection of MMP12 in a sub-
type of EPC, termed “Endothelial Colony Forming Cells” 
(ECFCs), resulted in inhibition of angiogenesis in vitro 
and in vivo [10]. 
MMP12 is a metalloelastase first identified as a 
protein secreted by macrophages [11]. MMP-12 shares 
many features typical of MMPs including the capacity 
to hydrolyze some extracellular matrix components 
[12]. Even so, while MMPs commonly facilitate tumor 
progression, MMP12 displays a controversial role in 
cancer progression [13]. In fact, despite evidences about 
correlation of tumor MMP12 with poor prognosis in 
several tumors [14-16], there are growing evidences about 
the “protective role” of MMP12, in tumor progression. 
Notably, overexpression of MMP-12 is associated 
with reduced tumor growth rates in mice, leading to a 
favourable outcome [17]. Some authors showed that the 
effect of MMP12 is determined by cell-type expression: 
when expressed by host macrophages, it has a protective 
effect, while when expressed by tumor cells it did not 
[18]. These observations may possibly account for the 
failure of clinical trials which rely on the use of broad-
range MMP inhibitors [19-20]. Taken together these 
data indicate that the role of MMP12 in human cancer 
is still much discussed and that it depends on its specific 
protein target and cleavage products. The anti-tumor and 
anti-angiogenetic activity of MMP-12 is often ascribed 
to the generation of angiostatin from plasminogen [21-
22]. Another potential target of MMP12 is uPAR, which 
can be cleaved, thus abolishing uPA-induced endothelial 
cell proliferation [23]. On these basis and on the above 
mentioned results obtained in our laboratory [7-9], 
MMP12 could be considered and used as a biological 
drug thus opening a new anti-tumoral therapy focused on 
uPAR cleavage. In this study we evaluated the possibility 
to deliver MMP12 into tumor mass where it could cleave 
uPAR of tumor cells and ECs.
Many studies suggest a role of Endothelial 
Progenitor Cells (EPCs) in tumor vascularization and 
metastasis [24]. EPCs are selectively recruited within the 
tumor mass [25], the amount of circulating EPCs positively 
correlates with tumor progression and their levels decrease 
after chemotherapy [26]. Also, Mesenchymal stem cells 
(MSCs) are able to support tumor angiogenesis and tumor 
development by providing the matrix required for new 
vessels and tumor cells scaffolding [27-28]. Due to their 
capability to home within tumors, EPC and MSC can be 
proposed to be used in the anti-cancer “cell therapy” as 
cellular vehicles for delivering molecules inhibiting cancer 
progression. 
The aim of our study was directed to control the 
progression of those tumor which heavily depend on 
uPAR to perform invasion and metastasis. As tumor model 
we utilized melanoma cell lines derived from patients with 
cutaneous melanoma.
Here we used MSCs as tumoral promoters by 
co-injecting them in mice together with cancer cells 
to favour tumor development and showed that MSCs 
promoted cancer development. On the other side, ECFCs, 
engineered with a lentivirus encoding MMP12, have 
been used as carriers of the anti-tumor uPAR-degrading 
enzyme. We first demonstrated that intravenous injected 
111In-oxine labelled ECFCs are able to home into tumor 
mass by exploiting the CXCR4/SDF1 axis. We also 
demonstrated that the i.v. injected MMP12- engineered 
“commandos ECFCs” were able to control melanoma 
progression, angiogenesis and metastasis and, at the same 
time, to cleave uPAR on tumor cells and endothelial cells 
of the tumor microenvironment in human melanomas 
transplanted in nude mice. Our results show that 
administration of autologous 111In-oxine labelled MMP12-
lentiviral modified ECFCs can provide a theranostic 
appoach to human melanoma progression and metastasis.
RESULTS
Role of tumor microenvironment on full length 
uPAR-dependent invasivity of melanoma cells 
We evaluated the correlation between uPAR 
levels and the invasive properties of three different 
melanoma cell lines (M14, Mewo, and A375). A375 
cells displayed higher uPAR mRNA (Fig.1A) and protein 
levels, as demonstrated by Western blotting analysis 
and densitometric evaluation (Fig.1B) as well as higher 
invasion activity compared to the other cell lines (Fig.1C). 
In all the cell lines uPAR is mainly present in its biological 
full length form and only a minor part is cleaved. On the 
basis of these results, we chose A375 melanoma cells to 
perform the following experiments. The invasive property 
of melanoma cells is mainly uPAR-dependent and it is 
inhibited in the presence of anti-uPAR R3 antibody, as 
demonstrated in fig 1E, pictures 1 and 2. To investigate 
the influence of the tumor microenvironment on uPAR 
expression and invasiveness of A375 melanoma cells 
we incubated melanoma cells with CM-MSC or CM-
ECFC and we observed an increased uPAR expression 
both at mRNA and protein levels (Fig.1D). Western 
blotting analysis with the anti-uPAR R4 antibody, 
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which recognizes both full length and truncated uPAR, 
demonstrated that the molecular form of upregulated 
uPAR is mainly the native D1+D2+D3 molecule (Fig.1D). 
Moreover, CMs treatment increased invasive properties of 
melanoma cells in an uPAR-dependent manner (Fig.1E), 
since CM-induced invasion was impaired by anti-uPAR 
R3 antibody. We previously demonstrated that the full 
length uPAR is required to perform invasion and that 
uPAR cleavage by the matrix metalloproteinase 12 
(MMP12) strongly decreased uPAR-dependent invasion 
of tumor cells and endothelial cells [8-10]. Therefore, we 
investigated whether CMs treatment affected MMP12 
synthesis and, consequently, uPAR truncation. CM-
MSC and CM-ECFC treatment induced MMP12 down 
regulation both at mRNA and protein level (Fig.2A), 
which could account for the CM-dependent up-regulation 
of the full length form of uPAR (Fig.1D) and the increased 
invasiveness (Fig.1E) of A375 cells. In agreement with 
these observations, treatment of A375 with MMP12 
blocking antibody resulted in the disappearance of uPAR 
cleaved fragment and enhanced full-length uPAR (Fig.2B) 
as well as A375 invasiveness (Fig 2C). We observed the 
same results also with CM-treated A375 cells, in which 
the treatment with anti-MMP12 antibody induced up-
regulation of full length uPAR and the increased invasion 
(data not shown). Afterwards, we transiently transfected 
A375 melanoma cells with a MMP12 cDNA containing 
vector (A375-MMP12) and analyzed their biological 
Figure 1: uPAR regulates invasion of melanoma cells. Panel A: uPAR expression in A375, Mewo and M14 melanoma cells 
determined by qRT-PCR. Results are normalized to the expression of ribosomal 18s. Panel B: Western blotting detection of full-length and 
truncated form of uPAR in melanoma cells. Three experiments were performed for each cell line. GAPDH expression functions as a control 
for protein loading. Panel C: Matrigel invasion of A375, Mewo and M14 under control conditions. In all invasion assays cells migrating 
through the Matrigel on the filters of Boyden chambers were counted after 6h and expressed as the total cell number of invading cells/filter. 
Data presented in panel A and C result from 3 independent experiments expressed as means ± SD. * P<0.05 or ** P<0.001, with respect 
to A375 melanoma cells. Panel D: uPAR expression, evaluated by qRT-PCR and by Western blotting in A375 melanoma cells in control 
condition and after overnight incubation with conditioned medium of MSC (CM-MSC) and ECFC (CM-ECFC). Data result from three 
independent experiments ± SD. Asterisks indicate significant difference (** P<0.001) with respect to control. Panel E: Pictures shown 
here represent Matrigel-coated filters of a typical invasion experiment of A375 melanoma cells in control condition and after stimulation 
with CM-MSC or CM-ECFC, in the absence and in the presence of anti-uPAR antibody R3. Four experiments were performed for each 
experimental condition. Histogram on the right shows the quantification performed as in C. Asterisks (* P<0.05) indicate significant 
difference between the indicated experimental condition.
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characteristics with respect to empty vector transfected 
cells (A375-EV). MMP12 transfection was effective in 
upregulating MMP12 mRNA levels and in increasing 
the release of active protein into the culture medium as 
revealed by Western blotting analysis and by elastin 
zymography (Fig.3A). Moreover, we demonstrated that 
released MMP12 was able to cleave uPAR: by incubating 
standard uPAR with CM from EV transfected cells (CM-
A375-EV) or from MMP12 tranfected cells (CM-A375-
MMP12) only CM-A375-MMP12 truncated standard 
uPAR (Fig.3B). At the same time transfected A375 
expressed the truncated form of uPAR on their surface, 
revealed by Western blotting of cell lysates with the 
specific anti-uPAR R4 antibody (Fig.3C). Moreover, the 
invasive property of A375-MMP12, exhibiting cleaved 
uPAR, was very low as compared to Matrigel invasion 
of A375-EV, which displayed full length uPAR (Fig.3D). 
To further evaluate whether MMP12-mediated uPAR 
cleavage is responsible for inhibition of cell invasion, 
we neutralized MMP12 in A375-MMP12 cells by using 
anti-MMP12 antibody. In this experimental conditions 
melanoma cells expressed full length uPAR (fig. 3C) and, 
at the same time, the invasion property was completely 
recovered (fig.3D). On the other hand, in the presence of 
irrelevant IgG A375-MMP12 cells expressed truncated 
uPAR and displayed a decreased Matrigel invasion.
Figure 2: MMP-12 down-regulation correlates with high levels of full length uPAR and A375 invasiveness. Panel A: 
MMP12 levels of A375 were examined by qRT-PCR in control condition or after overnight treatment with CM-MSC or CM-ECFC. 
Results are normalized to control (assumed as value 1). Asterisks indicate significant difference (* P<0.05; ** P<0.001) from control. 
MMP12 released in the medium by the same cells was evaluated by Western blotting (on the right). The result is representative of three 
separate experiments. Ponceau on the right shows equal loading. Panel B: Western blotting analysis of uPAR expressed by A375 cells in 
control condition and in the presence of anti-MMP12 antibody. Result is representative of three independent experiments. Panel C: Pictures 
represent the Matrigel-coated filters of an invasion experiment of A375 cells in the same experimental condition described above (panel B). 
Histogram shows the quantitative analysis of Matrigel invasion. Asterisks indicate significant difference (* P<0.05) from control. 
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Notably, MMP12-transfected A375 cells were 
unable to respond to CM-MSC stimulation in terms of cell 
migration when compared to A375-EV. This effect was 
due to the release of active MMP12 by transfected cells, 
which cleaved CM-MSC-up-regulated uPAR, as showed 
by Western blotting of cell lysates (Fig. 3D, pictures 5 and 
6). 
Role of SDF1-CXCR4 system in in vitro 
recruitment of microenvironmental cells (ECFC, 
MSC)
Recruitment of EPCs and MSCs in neoplastic 
tissues is a complex process primarily regulated by the 
interaction of various chemokines with their receptors. 
We evaluated the expression of SDF1/CXCR4 system in 
MSCs, ECFCs and tumor cells, as shown in Fig 4. PCR 
analysis revealed that MSCs expressed high level of SDF1, 
ECFCs expressed the related CXCR4 receptor, while 
A375 cells expressed very low levels of both CXCR4 and 
SDF1 genes (Fig.4A). Incubation of A375 with CM-MSC 
or CM-ECFC up-regulated the expression of SDF1 and 
its receptor (Fig. 4B). These results prompted us to use: i) 
MSCs as tumoral promoters by co-injecting them in mice 
together with melanoma cells and ii) ECFCs as carriers of 
MMP12, which can be recruited within tumors following 
the chemotactic gradient of SDF1 expressed by MSCs, 
normally present in tumors, but also able to up-regulate 
SDF1 expression in tumor cells [35]. Before in vivo 
experiments, we evaluated whether the SDF1/CXCR4-
dependent ECFCs recruitment into tumor mass could be an 
Figure 3: MMP12 inhibits uPAR-dependent invasion of A375 melanoma cells. Panel A: transient transfection of A375 cells 
with the recombinant vector pCDNA3.1 + MMP12 (MMP12) or empty vector pCDNA3.1 (EV) as control. RT-PCR analysis of MMP12 
in transfected cells (on the left) and Western blotting analysis of MMP12 released in the medium by the same cells (on the right). The 
enzymatic activity of MMP12 was revealed by the zymographic assay of CM from transiently transfected cells on α-elastin gel (low on 
the right). Panel B: Western blotting analysis of standard uPAR (st) incubated with aliquots of the culture medium EV (CM-A375-EV) and 
MMP12 A375 cells (CM-A375-MMP12). Panel C: Western blotting analysis of uPAR expression in A375-EV (mainly full length uPAR) 
and A375-MMP12 cells (truncated uPAR) in the absence and in the presence of anti-MMP12 antibody or irrelevant IgG. All the images 
in panels A-C are representative of 3 different experiments that gave similar results; Panel D: Representative fields of invasive transiently 
transfected A375 cells (empty vector and MMP12), in the presence or absence of anti-MMP12 antibody or of an irrelevant IgG (picture 
1-4). Pictures 5 and 6 show the Matrigel invasion of control A375 cells and of MMP12 transfected cells incubated with CM-MSC. The bar 
chart represents the relative quantification of Matrigel invasion performed by counting migrated cells as described in Figures 1A. Results 
show data from three independent experiments performed in triplicate. Asterisks indicate significant difference from control (A375-EV) 
(* P<0.05;). Full length and truncated form of uPAR in lysates of A375 cells in the conditions shown in pictures 5 and 6 of panel D, was 
evaluated by Western blotting using R4 anti-uPAR antibody.
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Figure 4: The Stromal cell-derived factor-1/CXCR4 system promotes ECFC recruitment in in vitro and in vivo. 
Expression of CXCR4/SDF1 system in A375, MSC and ECFC cells evaluated by RT-PCR analysis in basal conditions (panel A), in A375 
cells incubated with CM-MSC and with CM-ECFC (panel B). Panel C: SDF-1 expression after the knockdown of SDF-1 gene in MSC. 
Panel D: ECFC Matrigel invasion by adding in the lower compartment of Boyden chamber of: control media (picture 1); conditioned media 
from A375 (picture 2); CM-MSC (picture 3), and CM from cocolture A375/MSC (picture 5). Picture 4 and 6 show ECFC invasion upon 
addition in the lower compartment of CM from SDF1-silenced MSC or from A375/MSC SDF1-silenced cocolture, respectively; picture 
7 and 8 show the invasion of ECFC in the presence of anti-CXCR4 antibody, in control condition (picure 7) and after CM-co-colture 
incubation (picture 8). Histogram on the right represent the quantification of Matrigel invasion performed by counting migrated cells as 
described in Figures 1A. Asterisks (* P<0.05) indicate significant difference between the indicated experimental condition. Panel E: in vivo 
experiments. A375 melanoma cells were injected alone (control) or together with MSC in CD1-nude mice and the development of tumor 
was followed by measuring the tumor volume. Five mice were used for each experimental condition and the results are the mean of 3 
different experiments performed in triplicate. Asterisks indicate significant difference (* P < 0.05) from control. Panel F: In vivo recruitment 
of ECFCs into tumor mass. CD1-nude mice were grafted subcutaneously with viable melanoma cells together with MSC and then ECFCs, 
radiolabelled with 111In 8-oxyquinoline (oxine), were injected intravenously when the tumor reached about 150 mm3 volume, in the absence 
or in the presence of anti-CXCR4 or irrelevant antibody. 24 hours after radiolabelled ECFCs administration, SPECT tomography was 
performed as described in material and method. SPECT images show a selective visualization of radioactive ECFCs in the tumor mass. 
Figure shows a representative experiment (n=3). On the left: SPECT images of ECFC engraftment in the tumor mass at 30 min and 24 
h (upper panel) and ECFC engraftment in the presence of irrelevant IgG or anti-CXCR4 antibody (lower panel). On the right: relative 
histogram of uptake efficiency.
Oncotarget3717www.impactjournals.com/oncotarget
experimentally supported possibility, by performing ECFC 
in vitro chemoinvasion assay upon addition of CMs in the 
lower well of the migration chamber. CMs from A375 
(CM-A375), from MSCs (CM-MSC) and from a coculture 
of mixed (2:1) A375 and MSCs (CM-A375/MSC) were 
prepared by maintaining the cells 24h in colture medium. 
As shown in Fig.4D, CM-A375 induced a small increase 
of ECFCs Matrigel invasion, while CM-MSC were more 
effective. This effect was further strengthened by CM of 
A375/MSC co-cultures. To elucidate the involvement of 
SDF1/CXCR4 system, we performed in vitro Matrigel 
invasion of ECFCs after SDF1 siRNA treatment of 
MSCs (Fig.4C) or in the presence of CXCR4 blocking 
monoclonal antibody, taking in account for the toxic 
effect of CXCR4 siRNA. As a result of both treatments, 
ECFCs invasion was strongly impaired, thus indicating 
that ECFCs were recruited in vitro by SDF1 released by 
MSCs and also by cancer cells, as demonstrated by the 
inhibition of CXCR4/SDF1 in the co-colture experiments 
(Fig.4D). On the basis of these results, we investigated 
the in vivo role of MSC on tumor growth by injecting 
1×106 viable A375 cells alone or together with 0.5x106 
MSCs into CD-1 nude (nu/nu) mice, 6 to 8 weeks old (as 
described in Materials and Methods). Tumor development 
was monitored at regular intervals by measuring tumor 
diameters. We observed a drastic increase of tumor growth 
in the presence of MSCs co-injected with tumor cells (Fig. 
4E) thus confirming a protumoral role of MSCs. 
The in vivo recruitment of ECFCs into tumor 
mass depends on SDF1-CXCR4 interaction. 
To evaluate ECFCs homing into tumor mass in 
vivo, 25 days after tumor cell implantation, when tumor 
reached about 120 mm3 volume, mice were subjected to 
intravenous injection of 2x106 ECFCs labelled with 60 
μCi of 111In 8-oxyquinoline (oxine). After 24 hours from 
administration, the scintigraphic imagine showed that 
radiolabeled ECFCs were localized only in the tumor mass 
(Fig 4F). To evaluate the involvement of CXCR4 in the 
ECFCs recruitment, we performed the aforementioned in 
vivo experiment in the presence of anti-CXCR4 antibody 
to block the receptor on ECFCs cell membrane surface. 
In this condition we observed the failure of ECFCs to 
home into tumor mass, confirming the involvment of the 
SDF1/CXCR4 system in the in vivo recruitment of ECFCs 
(Fig. 4F). Homing efficiency has been evaluated using 
the analysis software Vivid as described in material and 
methods and expressed as uptake efficiency. We found 
that ECFC intratumoral engraftment in control mice was 
1.85% ± 0.2 compared to the muscle tissue controlateral 
while, in the presence of  anti-CXCR4 antibody, the 
uptake was significantly reduced to 0.6% ± 0.1 (Fig. 4F).
Construction of LV vector encoding MMP12. 
Characterization and activity of engineered 
ECFCs 
In order to deliver the anti-tumoral MMP12 into the 
tumor mass, we produced a lentivirus encoding MMP12 
and then we infected commandos ECFCs. We obtained 
engineered ECFCs able to release the relevant molecule 
(ECFC-MMP12) and ECFCs containing empty vector 
(ECFC-MOCK). Occurred infection was evaluated by 
PCR analysis of lysates and by Western blotting of the 
medium. As shown in Fig.5A ECFC-MMP12 expressed 
higher levels of MMP12 when compared to ECFC-MOCK, 
both at gene and protein level. To study the enzymatic 
activity of the released MMP12, we incubated standard 
uPAR with CM ECFC-MMP12 or CM ECFC-MOCK in 
the presence or absence of anti-MMP12 antibody and then 
we evaluated full-length and truncated uPAR by Western 
blotting analysis with anti-uPAR R4 antibody. CM ECFC-
MOCK did not cleave uPAR, whereas CM ECFC-MMP12 
produced truncated uPAR (Fig 5B). Such truncation was 
inhibited by anti-MMP12 antibody, but not by irrelevant 
IgG. Moreover, MMP12 over-expression prevented 
ECFCs capillary morphogenesis in a MMP12-dependent 
manner, since this effect was reverted by anti-MMP12 
antibody, while irrelevant IgG was ineffective (Fig.5C). 
To evaluate the potential of MMP12 gene-modified 
ECFCs as regard to uPAR-dependent tumor invasion and 
angiogenesis we performed A375 Matrigel invasion and 
capillary morphogenesis of control human microvascular 
endothelial cells (HMVEC) in the presence of CM ECFC-
MMP12 or CM ECFC-MOCK. As shown in Fig.5D and 
E, CM-ECFC-MMP12 impaired the invasion of A375 as 
well as the capillary morphogenesis of HMVEC when 
compared to CM-ECFC-MOCK, confirming a MMP12-
dependent anti-tumor and anti-angiogenic activity, 
as it was reverted by anti-MMP12 antibody. In these 
experiments we also demonstrated that the MMP12-
dependent anti-tumor and anti-angiogenetic activity were 
related to the presence of the truncated form of uPAR. In 
fact, the uPAR cleavage was reversed in the presence of 
anti-MMP12 antibody (fig 5 D, on the right and E, on the 
right).
As it is well known that MMP12 is able to cleave a 
number of other substrates, we evaluated this possibility 
in our experimental conditions. Some authors ascribed 
the anti-angiogenic and anti-tumoral role of MMP12 to 
the production of angiostatin from plasminogen. We did 
not reveal any angiostatin production (data not shown). 
To evaluate whether the invasion property of A375 in 
the presence of CM-MMP12 was due to direct effects 
of exogenously supplied MMP12 on Matrigel other than 
uPAR cleavage, we incubated overnight the Matrigel 
coated filter with CM ECFC-MOCK or CM ECFC-
MMP12 and then performed invasion assay of control 
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A375 cells. Such a treatment did not change the A375 
invasion properties (fig 5F). These results suggested that, 
in our experimental conditions, MMP12-mediated uPAR 
cleavage was required to inhibit A375 invasive properties.
Effect of MMP12- engineered ECFCs on tumor 
growth and metastasis in vivo
With the purpose to evaluate the therapeutic 
potential of ECFC-MMP12 for melanoma growth in 
vivo, a mixture of 1×106 viable A375 and 0.5x106 MSCs 
were co-injected into 6 to 8 weeks old CD-1 nude (nu/
Figure 5: The anti-tumoral efficacy of MMP12-engineered ECFC in vitro and in vivo. Panel A: Characterization of MMP12-
engineered ECFC. RT-PCR shows MMP12 expression of engineered ECFC and Western blotting analysis detects MMP12 released in 
conditioned medium of ECFC containing empty vector (CM-ECFC MOCK, lane 1) or containing lentiviral vector encoding MMP12 
molecule (CM-ECFC MMP12, lane 2). Panel B: Western blotting analysis of standard uPAR (st) incubated with aliquots of CM-ECFC 
MOCK (lane 1) and of CM-ECFC MMP12 (lane 2) in the presence of anti-MMP12 antibody (lane 3) or an irrelevant IgG (lane 4). Panel 
C: Capillary morphogenesis at 6h of ECFC-MOCK (picture1) and ECFC-MMP12 (Figure 2), in the presence of anti-MMP12 antibody 
(picture 3) or irrelevant IgG (picture 4). Numbers: percent field occupancy, taking control as 100%. Data are from 3 experiments performed 
in triplicate. Panel D: Anti-tumor property of ECFC-MMP12. Matrigel invasion of A375 cells in control conditions (picture 1) and upon 
addition, in the lower well of the migration chamber, of CM ECFC-MMP12 (picture 2), in the presence of anti-MMP12 antibody (picture 
3) or irrelevant IgG (picture 4). The histogram represents the quantification of Matrigel invasion experiments, evaluated as in Fig.1A. 
Asterisks (*: P<0.05) indicate significant difference between the indicated experimental condition. Full length and truncated form of uPAR 
in lysates of A375 melanoma cells, shown on the right, was evaluated by Western blotting in the same conditions described above. Data 
result from three independent experiments. Panel E: Anti-angiogenic property of ECFC-MMP12. Capillary morphogenesis of endothelial 
cells treated with CM-ECFC MOCK (picture 1) or CM-ECFC MMP12 (picture 2) in the presence of anti-MMP12 antibody (picture 3) 
or irrelevant IgG (picture 4). Numbers: percent field occupancy, taking control as 100%. The pictures are representative of 3 different 
experiments performed in triplicate that gave similar results. Full length and truncated form of uPAR in lysates of endothelial cells, shown 
on the right, was evaluated by Western blotting in the same conditions described above. Panel F: Histogram represents number of A375 
cells allowed to invade across the Matrigel pre-incubated overnight with CM ECFC MOCK and CM ECFC MMP12. 
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nu) mice together with 0.5x106 ECFC-MMP12 or ECFC-
MOCK. In the presence of ECFC-MMP12 tumor growth 
was strongly inhibited: after 25 days the volume of tumors 
containing ECFC-MM12 was 0.4±0.15 cm3 compared to 
1.2±0.2 cm3 tumor containing ECFC-MOCK (Fig 6A). 
The presence of viable ECFCs as well as the presence 
Figure 6: The in vivo effect of MMP12-engineered ECFC on tumor growth and metastasis. Panel A. Melanoma tumors were 
obtained by subcutaneous injection of 1×106 viable A375 cells together with 0.5x 106 MSCs in the flanks of 6-week-old nude nu/nu (CD-1) 
and, when tumor mass was evident, mice were treated by i.v. injection with ECFC-MOCK or ECFC-MMP12, as described in materials and 
methods. The days of injection are depicted on the chart using big arrows. Effect of ECFC-MMP12 on in vivo tumor growth. Mixture of 
A375 melanoma cells and MSC were co-injected together with ECFC-MOCK or ECFC-MMP12 in nude mice. Tumor development was 
monitored for 25 days, by measuring tumor diameter, and then mice were sacrificed. Asterisks indicate significant difference (*: P < 0.05) 
from control. Panel B: uPAR and Flag levels assessed by immunohistochemistry in tumor tissue from mice treated as indicated in A and 
collected at the end of the experiment, as described in results section. These results are representative of 3 different experiments performed 
in triplicate that gave similar results (magnification: x 100 in the upper panels and x 400 in the lower panels). Panel C: Tumor growth curve 
was obtained by measuring tumor diameters at regular intervals. Eight mice were used for each experimental condition Statistical analysis 
was carried out by Student’s t-test and significant differences between the two groups were indicated by the asterisks (**: P < 0.001 from 
control ECFC-MOCK). Panel D: Histological analysis of the tumors and lungs recovered at autopsy as described in the text. Tumor slides 
were performed according to standard procedures and incubated with a primary antibody against CD31, uPAR and FLAG (see Materials 
and Methods) followed by a peroxidase-conjugated IgG preparation; 3,39-diaminobenzidine was used as the chromogen for development. 
Slides werecounterstained with aqueous Meyer hematoxylin, mounted with glycerol for visual inspection and esamined under bright field 
microscope. Lungs were stained with hematoxylin–eosin. Metastases (depicted using big arrows) in the image of mouse injected with 
ECFC MOCK come from two different slides of the same lung. Pictures are representative of four randomly chosen microscopic fields 
(magnification: x 400).
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of full-length uPAR were evaluated in recovered tumor 
mass by immunohistochemical analysis (Fig 6B). On 
the basis of the use of FLAG expression vectors in the 
construction of lentivirus, the presence of ECFCs was 
estimated by using an anti-FLAG antibody while the 
efficiency of uPAR cleavage was evaluated by a mAb 
which recognizes only the full-length native form (uPAR 
N-19, Santa Cruz). Anti-FLAG antibody stained tumors 
explanted from mice injected with ECFC-MMP12 as well 
as with ECFC-MOCK, thus demonstrating that engineered 
ECFCs remained within tumor mass. The anti-uPAR 
N-19 antibody stained only tumor cells of ECFC-MOCK- 
treated mice, while the staining was strongly reduced in 
tumor mass of mice treated with ECFC-MMP12 (fig. 
6B). These results demonstrated the MMP12-dependent 
cleavage of full length uPAR, which is in agreement with 
the inhibition of tumor growth by ECFC-MMP12 (Fig. 
6A).
To evaluate the effect of MMP12-dependent uPAR 
cleavage on tumor growth and on metastasis development 
in tumor bearing mice, we injected ECFC-MMP12 or 
ECFC-MOCK when tumor mass was evident in all the 
mice injected with A375 cells and MSC. We observed 
a significant decrease of tumor growth in mice which 
received i.v. ECFC-MMP12, while in mice treated with 
ECFC-MOCK the tumor continued to grow (Fig. 6C). At 
the end of treatment tumor mass and lung were subjected 
to histological analysis (Fig 6D). We demonstrated the 
presence of injected ECFCs in tumor mass of all the mice 
by using an anti-FLAG antibody. We also examined the 
presence of full-lenght uPAR using the anti-uPAR N-19 
antibody and angiogenesis by using anti-CD31 antibody. 
Both antibodies stained only tumor cells of ECFC-MOCK-
treated mice, while the staining was strongly decreased in 
tumor mass of mice treated with ECFC-MMP12. These 
results are indicative of a MMP12-dependent cleavage 
of full length uPAR and the intratumoral angiogenesis 
inhibition, which are in agreement with the inhibition of 
tumor growth. We also examined the lungs to evaluate 
the presence of metastasis. The ECFC-MMP12 treated 
mice did not show any metastasis, while the control 
mice exhibited a mean of 5-6 metastasis/lung, thus 
demonstrating an anti-metastatic effect of injected ECFC-
MMP12. 
In fig. 7 is shown a schematic representation of 
our results: ECFC-MMP12 recruited in tumor mass, by 
exploiting the CXCR4/SDF1 system, released the MMP12 
anti-tumor uPAR degrading enzyme, thus impairing tumor 
growth and angiogenesis. 
Figure 7: Schematic representation of the concept of ECFCs as cellular vehicles delivering anti-tumor uPAR degrading 
enzyme. ECFCs derived from cord blood, were transduced with lentiviral vectors encoding the matrix metalloproteinase 12 (MMP12). 
Subcutaneous tumors were developed by direct co-injection of A375 and MSCs. Six days after tumor cells implantation, genetically 
modified ECFCs labelled with 60 μCi of 111In 8-oxyquinoline (oxine) were injected intravenously into CD-1 nude (nu/nu). 24 hours later 
the scintigraphic imagine showed that radiolabeled ECFCs were localized only in the tumor mass. High expression of SDF1 by tumour 
cells and MSCs form a local gradient of the chemokine in the tumour region. CXCR4-expressing ECFCs are thus recruited to the tumour, 
where they release active MMP12 enzyme which cleaves uPAR impairing angiogenesis and tumor growth. 
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DISCUSSION
Tumor progression is characterized by increased 
expression of uPA/uPAR system [7]. This system is finely 
modulated: it is transiently expressed whenever cell 
movement is required, as in inflammation, wound repair 
and tumors, while its expression is low in normal quiescent 
tissues. In the tumor microenvironment uPAR is expressed 
not only in tumor cells but also in endothelial cells (EC), 
fibroblasts, inflammatory cells (macrophages, neutrophils) 
and in MSC thus becoming an attractive target for cancer 
therapy [36, 37]. Our previous studies [8, 10]showed that 
movement of endothelial and cancer cells depends on 
the native full-lenght uPAR, and that truncation of uPAR 
domain 1 by MMP12 results into the loss of their invasion 
properties. In the last years a new idea about the role of 
MMPs in cancer is emerging. Several MMPs, including 
MMP12, display a protective effect by suppressing tumor 
growth, thus accounting for the failure of clinical trials 
which employed broad-range MMP inhibitors [17, 20]. 
Several strategies are emerging to target uPAR 
[38, 40]. A new anti-cancer therapeutical strategy is the 
“targeted therapy”, as opposed to traditional nonspecific 
chemotherapy, thus reducing pharmacological side effects 
and increasing the efficiency of the therapeutic approach. 
Due to its activity, MMP12 can be considered a biological 
drug to be used in targeted anti-uPAR therapy. To deliver 
such molecules the so-called “cell-based therapies” are 
becoming more relevant. Due to their capability to home 
within tumors, MSC and EPCs are considered the best 
candidates to be used as “Trojan Horses” carrying anti-
cancer drugs [41-43].
EPCs play an important role in tumor vascularization 
and metastatic transition either by their incorporation in 
vessels or by supporting tumor angiogenesis via paracrine 
secretion of proangiogenic cytokines. EPCs are selectively 
recruited within the tumor mass [41]. The amount 
of circulating EPCs positively correlates with tumor 
progression and their levels decrease after chemotherapy 
[26]. Mesenchymal stem cells (MSCs) are involved in 
tumor growth by providing a stromal support and by 
secreting angiogenic factors. Subcutaneous co-injection of 
MSC and tumor cells exalts tumor progression [27, 28]. 
Moreover, over-expression of uPA-uPAR in tumors plays 
an important role in recruitment of MSC in malignant 
solid tumors [44].
Here we manipulated ECFCs, a sub-type of EPCs, 
as cellular vehicle to deliver MMP12 into the tumor 
mass with the aim to truncate uPAR both in endothelial 
and tumor cells. We chose the solid tumor melanoma 
because its distinctive features: it often affects patients < 
60 years, its prognosis is mostly related to the thickness 
of primary tumor in the skin and in its late phases (stage 
IV) it is poorly responsive to conventional treatments. 
We hypothesized that delivery of ECFCs engineered to 
express MMP12 into human melanomas transplanted in 
nude mice could release such metalloproteinase into tumor 
mass thereby controlling melanoma progression. 
In this study we first confirmed that uPAR 
levels correlated with tumor malignancy in different 
melanoma cell lines and then we evaluated the role of 
microenvironment on the invasive properties of melanoma 
cells. We demonstrated that incubation of melanoma cells 
with CM-ECFC or CM-MSC increased the invasion of 
tumor cells, which depends on the up-regulation of full 
length uPAR. This treatment also induced the down-
regulation of MMP12, which is in agreement with 
full length uPAR-dependent tumor malignancy, thus 
confirming a “protective role” of MMP12 in cancer 
invasivity. To further verificate the role of MMP-12 in 
inhibiting tumor invasion, we transiently transfected 
A375 melanoma with MMP12 expression vector and 
demonstrated that its consequent upregulation impaired 
uPAR-dependent melanoma cell invasion.
It is known that EPCs recruitment into tumoral 
tissues depends on the interaction of tumor chemokines 
with related receptors expressed on EPCs. In particular, 
CXCR4/SDF1 system plays a pivotal role in EPCs tumor 
homing [45-48]. Herein, we demonstrated that ECFCs 
express CXCR4 on their surface, while MSCs secrete large 
amounts of SDF1. Moreover, melanoma cell incubation 
with CM-ECFC or CM-MSC greatly up-regulated this 
system. We have also shown that the in vitro invasivity of 
ECFCs and in vivo ECFCs tumor homing depend on the 
interaction between CXCR4 of ECFCs and SDF1 released 
by MSCs and melanoma cells.
On the basis of these results, we used MSCs as 
tumoral promoters by co-injecting them in mice together 
with melanoma cells, with the aim of enriching tumor 
microenvironment with SDF-1 molecular magnets able to 
recruit ECFC-MMP12. 
We engineered ECFCs with a lentivirus encoding 
the uPAR-degrading enzyme MMP12 in order to induce 
a lentivirus-dependent “gain of function” of MMP12 
activity in ECFCs. This ex vivo manipulated ECFCs lost 
the capacity to perform capillary morphogenesis in vitro 
and, at the same time, acquired the anti-tumor and anti-
angiogenetic activity thus impairing invasion of melanoma 
cells and the capillary morphogenesis of control ECs. In 
vivo co-injection of melanoma cells with ECFC-MMP12 
strongly inhibited tumor growth and, at the same time, 
cleaved uPAR. These results are strongly suggestive of 
an uPAR-dependent inhibition of tumor angiogenesis and 
tumor spread. Finally, the i.v injection of ECFC-MMP12s 
in melanoma bearing mice induced a significant decrease 
of melanoma growth and inhibited the development 
of lung metastasis. Immunohistochemical analysis of 
tumor mass revealed that the delivered ECFCs remained 
viable within implanted melanomas. Simultaneously, 
we observed a lower amount of full length uPAR and 
inhibition of angiogenesis. While confirming the data 
obtained in vitro these results also indicate that the release 
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of MMP12 by engineered ECFCs recruited in the tumor 
mass impairs tumor growth and metastasis mainly by 
inhibiting uPAR-dependent angiogenesis and spread of 
melanoma cells. 
Many viral constructs have been designed to deliver 
new therapeutic information into cancer cells, but none of 
such viruses include an MMP12 construct. In this study 
we suggest, for the first time, the employment of MMP12 
as biological drug in the anti-tumoral cell-based therapy 
in order to impair tumor angiogenesis and tumor invasion 
of melanoma and of all those tumor which heavily depend 
on uPAR to perform invasion. 
Knowledge sprouting from these results indicate 
the possibility to reduce tumour angiogenesis and 
tumor progression in melanoma-bearing patients 
through injection of autologous EPCs able to deliver the 
MMP12 anticancer agent into tumor mass, which could 
inhibit all the uPAR-dependent melanoma progression 
characteristics. EPCs are a minor component of circulating 
cells, but a series of methods are available for their 
separation and ex-vivo expansion from human blood after 
a proper stimulation of bone marrow [49, 50]. The use of 
autologous ECFCs represent an effective melanoma tumor 
treatment without rejection risk, that may cooperate with 
standard therapy. 
Results of this research have a translational 
relevance and a potential impact for the health system 
related to a better control of metastatic disease in 
melanoma. An approach based on i.v. injection of MMP12-
engineered ECFCs, able to impair tumor progression 
(therapy), and on the labelling of ECFC with 111In-oxine 
for molecular imaging of primary and metastatic tumor 
masses (diagnosis), provides a new and promising 
MMP12 theranostic approach to human melanoma and to 
future cancer medicine for all the tumor displaying uPAR-
dependent cancer progression. 
MATERIAL AND METHODS
Cell lines
Endothelial Colony-Forming-Cells (ECFCs), 
a subpopulation of EPCs, were isolated from >50 ml 
human umbilical cord blood (UCB) of health newborns, 
as described [10], after maternal informed consent and 
in compliance with Italian legislation, and analyzed for 
the expression of surface antigens (CD45, CD34, CD31, 
CD105, ULEX, vWF, KDR, uPAR) by flow-cytometry 
[10]. Human microvascular endothelial cells (HMVEC) 
are available in our laboratory. Mesenchymal Stem Cells 
(MSCs) were obtained from bone marrow aspirates of 
donors which signed informed consent, and were expanded 
according to published methods (29). MSC were analyzed 
at P0 and P12 for the expression of surface antigens CD45, 
CD14, CD44, CD166, CD90, CD73, HLA-DP, -DQ, -DR, 
HLA-ABC, CD105, CD271 APC (FACSCalibur, Becton 
Dickinson). At P0 and P6 an aliquot of cells was used to 
test the adipo- and osteo-differentiation capabilities. The 
melanoma cell lines A375 and Mewo were obtained from 
American Type Culture Collection (Manassas, VA) and 
grown in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% FBS (Euroclone). M14 melanoma cells were 
available in our laboratory.
Preparation of conditioned medium (CM-ECFC 
and CM-MSC)
ECFC and MSC cells were seeded at density of 2.0 
× 105 cells/ml in complete media into T-75 tissue culture 
flasks and grown to approximately 80% confluency. Cells 
were collected washed twice with phosphate-buffered 
saline (PBS) and incubated overnight in 2% FCS medium. 
Overnight condition media were collected and centrifuged 
at 700 g at room temperature for 5 min to pellet cells. The 
supernatant was collected and centrifuged at 2000 g at 
4°C for 10 min to remove cell debris. The supernatant 
representing ECFC-CM and MSC-CM was divided into 
two aliquots one subjected for MMP12 detection and 
the second aliquot was used for conditioning A375 cells. 
In some experiments, conditioned medium (CM) was 
prepared with MSCs pretreated with small-interfering-
RNA (siRNA) and negative control constructs obtained 
from Riboxx Life Sciences/Euroclone (IBONI siRNA-
pool, targeting human SDF1). siRNA constructs were 
incorporated into RiboxxFECT transfection reagent 
according to the manufacturer’s instructions. Cells were 
incubated for 48 hours with transfection mix. 
Western blot analysis, semiquantitative and 
quantitative PCR.
Aliquots of culture media (20 µl) and lysates 
(40μg) of A375 incubated for 24 hours with CM-ECFC 
or CM-MSC, were subjected to Western blotting. The 
primary antibodies were: anti-uPAR R3 (1:1000; mouse 
monoclonal antibody, BioPorto Diagnostics), which 
recognizes the full-length uPAR; anti-uPAR R4 (1:1000 
mouse monoclonal antibody, BioPorto Diagnostics) 
which reveals both the full-length and truncated form of 
uPAR; anti-MMP12 (1:1000; rabbit polyclonal antibody, 
Millipore) and anti-GAPDH (mAbcam 9484) as loading 
control. After incubation with horseradish peroxidase–
conjugated donkey anti-mouse or anti-rabbit or anti-
goat IgG (1:10,000) for 1 hour, immune complexes were 
detected with an enhanced chemiluminescence ECL 
detection system (GE Healthcare). The membranes were 
exposed to autoradiographic films for 1–10 minutes. 
Total RNA was prepared using Nucleospin RNA II 
(Macherey-Nagel), agarose gel checked for integrity, and 
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reverse transcribed with GoScript system (Promega) using 
random primers according to manufacturer’s instructions. 
Selected genes were evaluated, before and after CM-
ECFC and CM-MSC treatment, by a quantitative Real-
Time (RT)–PCR with 7500 Fast Real Time PCR System 
(Applied Biosystems) and determined by the comparative 
Ct method using 18S ribosomal RNA as the normalization 
gene. Amplification was performed with the default PCR 
setting: 40 cycles of 95°C for 15 seconds and of 60°C for 
60 seconds using SYBR Green–based detection (GoTaq 
qPCR Master Mix; Promega). mRNA levels of uPAR, 
CXCR4, MMP12 and SDF-1 were determined by an 
internal-based semiquantitative RT–PCR, (MJ Research) 
using procedures previously described [10, 30]. GAPDH 
was used as loading control. The reaction products were 
analyzed by electrophoresis in 2% agarose gel containing 
ethidium bromide. Primer sequences (IDT, TemaRicerca) 
are reported in Table 1.
Invasion assay and capillary morphogenesis.
Cells invasion was studied in Boyden chambers in 
which the upper and lower wells were separated by 8 μm–
pore size polycarbonate filters coated with Matrigel (50 
μg/filter; BD Biosciences). Cells (15×103) were placed in 
the upper well, and invasion was performed for 6 hours 
at 37°C-5% CO2 as previously described [8, 10]. A375 
invasion was also evaluated either by adding CM-ECFC 
or CM-MSC in lower well or after 24 hours preincubation 
with DMEM–2% FCS, or with CMs-2% FCS. In some 
experiments, invasion was performed in the presence of 
2 μg/ml uPAR-neutralizing antibody R3 or anti-MMP12 
polyclonal antibodies, or anti CXCR4 (R&D Systems) 
or irrelevant IgG (Sigma). Some invasion experiments 
were performed with the A375 transiently trasfected 
with MMP12. In some chemoinvasion experiment 
the filters coated with Matrigel were pre-incubated 
overnight with CM ECFC MOCK and CM ECFC 
MMP12. The day after the CM removed and untreated 
A375 allowed to invade out of the matrix, across the 
membrane.
In vitro capillary morphogenesis was performed 
as described [10] in tissue culture wells coated with 
Matrigel. ECFCs or HMVECs were plated (18x103/well) 
in EBM-2 medium, supplemented with 2% FCS and 
incubated at 37°C-5% CO2, under condition described 
in Fig 5. Results were quantified at 6h by measuring the 
percent field occupancy of capillary projections. Six to 
nine photographic fields from three plates were scanned 
for each point. Results were expressed as percent field 
occupancy ± SD with respect to control fixed at 100%.
MMP12 transient transfection and uPAR cleavage
The cDNA-containing vector and the empty 
plasmid (15 μg each of either pCDNA3.1 + MMP12 or 
pCDNA3.1 alone; Invitrogen) were transiently transfected 
into A375 cells using Lipofectamine Tranfection Reagents 
(Invitrogen Co.)[10]. Briefly, 3.5×105 cells/well were 
plated in six multiwell plates 24 hrs before transfection 
and then complete medium was replaced. Expression of 
MMP12 gene was measured by Real Time-PCR and the 
level of released protein was analyzed by Western blotting 
of culture medium. 
To verify MMP12-dependent uPAR cleavage, 25 
μg of recombinant human uPAR (R&D Systems) was 
incubated overnight at 37°C with 15 μl of DMEM–2% 
FBS or CM derived from empty vector or MMP-12 
transiently transfected A375 or with CM derived from 
ECFCs engineered to express MMP12. These experiments 
were performed in the absence and in the presence of anti-
MMP12 antibody (10 μg/ml), as described [10]. 
SDS-PAGE Zymography
MMP12 α-elastin-degrading activitiy was examined 
by electrophoresis of the culture medium under non 
reducing conditions in 12.5% polyacrylamide gels 
containing α-elastin (1.2 mg/ml) (Sigma Chemical Co.) 
[31]. After electrophoresis, the gels were washed in 2.5% 
Triton X-100 for 30 minutes and then incubated overnight 
at 37°C in elastase assay buffer. Lysis of the substrate in 
the gel was visualized by staining with Coomassie R-250 
(0.5% [wt/vol]), followed by destaining. 
Table 1:
Gene Forward primer Reverse primer
MMP-12 5’-tgctgatgacatacgtggca-3’ 5’-aggatttggcaagcgttgg-3’
MMP-12 5’-cctgctttgtcctttgatgc-3’ 5’-tgactcaatccctggaaagtc-3’
CXCR4 5’-gccttatcctgcctggtattgtc-3 5’-gcgaagaaagccaggatgaggat-3’
uPAR 5’-gcccaatcctggagcttga-3’ 5’-tccccttgcagctgtaacact-3’
SDF1 5’-actgggtttgtgattgcctctgaag-3’ 5’-ggaacctgaacccctgctgtg-3’
18s 
rRNA 5’-cggctaccacatccaaggaa - 3’ 5’-gctggaattaccgcggct -3’
GAPDH 5’-ccacccatggcaaattccatggca-3’ 5’-tctagacggcaggtcaggtccacc-3’
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Lentiviral vector construction, production and 
cell transduction
To construct LvPGK-MMP12Flag, the MMP12-Flag 
DNA sequence was amplified from the pCDNA3 plasmid 
using primers containing BamHI and BsrGI restriction 
sites (BamHI-5’cgggatcccgatggggaagtttcttc-3’ and BsrGI 
5’ctgctactgctatttatcgcacatgtgc-3’) and subsequently cloned 
in the lentiviral vector pRRLsin.PPT.hPGK.mcherry_pre 
(kindly provided by dr Marco Erreni, Humanitas Clinical 
and Research Center, Milan, Italy), replacing the mcherry 
sequence. Similarly, the LvPGK-Flag control vector was 
generated by synthesizing the Flag-tag sequence at 95°C 
for 1 hour, using primers containing BamHI, ClaI and 
BsrGI restriction sites (5’-cggga-tcccgtactacaaagacgatg
acgataaatagccatcgatggt-3’ and 5’-cgtgtacaccatcgatggcta
tttatcgtcatcgtctttgtag-tacgggatcccg-3’). All amplification 
conditions were settled using the Phusion Hot Start II 
high-fidelity DNA Polymerase (Finnzymes), according 
to manufacturer’s instructions. Sequence integrity was 
verified by standard sequence analysis (Primm srl, 
Milan, Italy). The third-generation lentiviral vectors 
were produced by transient transfection of 293T cells 
according to standard protocols [32]. Briefly, subconfluent 
293T-cells were co-transfected with 11,7 μg of the transfer 
plasmid, 5 μg of packaging plasmid, 3.5 μg of envelope 
plasmid and 5 μg of rev-expressing plasmid (ViraPowerTM 
lentiviral packaging mix, Invitrogen) by Lipofectamine 
(Invitrogen). After 16 h medium was changed, and 24 
h later recombinant lentivirus vectors were collected, 
filtered through 0.22-μm-pore-size cellulose acetate filters 
and immediately used. To determine the maximum viral 
efficiency, serial dilutions of freshly harvested conditioned 
medium were used to infect 105 ECFC in a six-well plate 
in the presence of Polybrene (8 μg/ml). After 24 hours 
ECFC were incubated with complete medium, EBM-2 
containing EGM-2 Single Quots (Lonza), and 48 h later 
analyzed for infection efficiency, by Western blot.
In vivo experiments
All procedures involving animals were performed 
in accordance with the ethical standards and according 
to the Declaration of Helsinki and according to national 
guidelines, approved by the ethical committee of Animal 
Welfare Office of Italian Work Ministry and conformed to 
the legal mandates and Italian guidelines for the care and 
maintenance of laboratory animals. 
To evaluate the effect of MSCs on tumor growth, 
five male CD1 immunodeficient mice (6–8 weeks old; 
Charles River Laboratories International) were injected 
subcutaneously with 100 μl of PBS containing 1x106 
A375 cells alone and five mice with A375 cells together 
with 0.5x106 MSCs. Tumor development was monitored 
at regular intervals by measuring tumor diameters by 
a calliper. Mice were sacrificed 25 days after tumor 
cell implantation and tumor growth was estimated by 
measuring the tumor volume determined by the formula: 
(L x W 2 )/2, where L and W are the length and width. 
For ECFCs tumor homing, ECFCs were resuspended 
in medium containing 100 μCi of 111In 8-oxyquinoline 
(oxine) (Perkin Elmer)/106 cells. After washing, 2-3x106 
111In 8-oxyquinoline (oxine) labeled cells were infused 
intravenously into 12 tumor bearing nude mice. Six 
tumor bearing mice were injected with labelled ECFCs 
pre-incubated with anti-CXCR4 antibody (R&D Systems, 
Minneapolis, MN; 10 μg/ml) and six mice were injected 
with labelled ECFCs pre-incubated with irrelevant IgG 
for 30 min. Animals were subjected to SPECT scan 
using the microPET/SPECT/CT Trifoil Imaging [33]. 
Postlabeling viability exceeded 80%, and preliminary 
experiments demonstrated adequate cell tracking. CT 
scan was performed followed by the SPECT tomography, 
starting at 30 min p.i. The CT/SPECT scan were acquired 
as previously described [34]. The energy window was 
set on the 111In photopeak ranging from 171 keV±10% 
and at 245 keV±10%. Once the scanning session was 
complete, animals were recovered in a housing unit and 
monitored until awake. The fused images were visually 
analyzed to detect the engrafted tumor mass or normal 
tissue and regional SPECT activities were measured 
using the analysis software Vivid (Gamma Medica-Ideas, 
Northridge, CA) by delineating the region of interest 
(ROI) of the tissue in the fused CT images. A similar ROI 
was generated for the muscle tissue on the contralateral 
side of the tumor. Tumor uptake efficiency (nTA) as 
related to the ROI under evaluation, was obtained using 
the following formula: nTA = TA-BA/BA, where TA is 
tumor activity, BA is background activity measured in the 
muscle tissue contralateral to the tumor and normalized to 
injected activity. The same formula was used to evaluate 
the uptake efficiency of different organs.
Evaluation of the therapeutic local effect of ECFC-
MMP12 on the tumor onset, were performed by co-
injecting A375 cells and MSCs into 10 nude mice together 
with 0.5x106 MOCK (5 mice) or ECFC-MMP12 (5 mice). 
The animals were monitored daily and were sacrificed 
after 18 days to evaluate tumor growth. The histological 
analysis of tumor mass was performed as described below. 
To evaluate the ECFC-MMP12 effect on in vivo 
tumor progression, we injected melanoma cells with MSC 
into nude mice and, after fifteen days, when the tumor mass 
was evident, we performed i.v. injection of engineered 2 
x 106 ECFCs, according to the following schedule: 8 mice 
were treated with ECFC-MOCKs and 8 mice with ECFC-
MMP12s. The treatment was repeated after three and six 
days and then tumor growth was followed by measuring 
the tumor volume for five additional days, before the 
tumour masses exceeded a size producing evident physical 
discomfort. Removed tumors and lungs were fixed 
overnight at 4°C in formalin (5% in PBS) for histological 
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analyses performed on paraffin-embedded sections, 
using the avidin-biotin-peroxidase complex method and 
diaminobenzidine tetrahydrochloride chromogen kit 
(Dako LSAB2; Dako Corporation, Carpinteria, CA). The 
sections were probed with anti-uPAR (N19, Santa Cruz 
Biotechnology), anti-Flag (cell Signaling), anti CD31 
(Thermo Scientific). Slides were counterstained with 
aqueous Meyer hematoxylin and mounted with glycerol 
for visual inspection and photography. To evaluate the 
metastatic potential of melanoma cells, the mice’s lungs 
were removed and the number of metastasis were counted 
under a stereomicroscope.
Statistics
Results are expressed as means ± SD. Multiple 
comparisons were performed by the Student test. 
Statistical significances were accepted at * p<0.05 and 
**p<0.001.
ABBREVIATIONS
uPAR: urokinase-type Plasminogen Activator 
Receptor; MMP12: Matrix-metallo-proteinase-12; 
HMVEC: Human Microvascular Endothelial Cell; ECFC: 
Endothelial Colony-Forming-Cell; MSC: Mesenchymal 
Stem Cell; SDF1: Stromal cell-derived Factor-1; CXCR4: 
CXC Chemokine Receptor 4; SPECT: Single Photon 
Emission Computed Tomography
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